COGT

Cogent Biosciences Inc

Add to Watchlist

Advanced Chart

12.450

+0.15(1.220%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.740

Open

12.050

VWAP

12.46

Vol

3.47M

Mkt Cap

1.74B

Low

12.012

Amount

43.24M

EV/EBITDA(TTM)

Total Shares

109.34M

1.60B

EV/OCF(TTM)

P/S(TTM)

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.589

-0.24%

-0.532

-16.87%

-0.513

+470.4%

Estimates Revision

The market is revising No Change the revenue expectations for Cogent Biosciences, Inc. (COGT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 178.52%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.52%

In Past 3 Month

Stock Price

Go Up

+178.52%

In Past 3 Month

10 Analyst Rating

26.51% Upside

Wall Street analysts forecast COGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COGT is 15.75 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

3 Hold

0 Sell

Moderate Buy

26.51% Upside

Current: 12.450

Low

7.00

Averages

15.75

High

25.00

26.51% Upside

Current: 12.450

Low

7.00

Averages

15.75

High

25.00

Citi

Buy

maintain

$15 -> $22

2025-07-18

New

Reason

Citi

Price Target

$15 -> $22

2025-07-18

New

maintain

Buy

Reason

Citi raised the firm's price target on Cogent Biosciences (COGT) to $22 from $15 and keeps a Buy rating on the shares. The firm says that following the results for bezuclastinib in non-advanced systemic mastocytosis, the drug is being viewed as upgrade over Blueprint Medicines' (BPMC) Ayvakit. Citi sees more data catalysts for Cogent.

Baird

Colleen Kusy

Neutral

maintain

$7 -> $9

2025-07-08

Reason

Baird

Colleen Kusy

Price Target

$7 -> $9

2025-07-08

maintain

Neutral

Reason

Baird analyst Colleen Kusy raised the firm's price target on Cogent Biosciences to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its model following the release of SUMMIT data in Non-AdvSM which was better than the worst case scenarion but worse than the best case.

H.C. Wainwright

Buy

upgrade

$12 -> $22

2025-07-08

Reason

H.C. Wainwright

Price Target

$12 -> $22

2025-07-08

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Cogent Biosciences to $22 from $12 and keeps a Buy rating on the shares after the company reported results from the Phase 3 SUMMIT trial evaluating bezuclastinib versus placebo in patients with non-advanced systemic mastocytosis. The results potentially establish bezuclastinib as the new standard of care for mastocytosis, the analyst tells investors in a research note. H.C. Wainwright increased its probability of approval for bezuclastinib in non-advanced systemic mastocytosis to 95% from 60%..

Jefferies

Buy

maintain

$23 -> $28

2025-07-07

Reason

Jefferies

Price Target

$23 -> $28

2025-07-07

maintain

Buy

Reason

Jefferies raised the firm's price target on Cogent Biosciences to $28 from $23 and keeps a Buy rating on the shares after Cogent announced the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis demonstrated "clinically meaningful and highly statistically significant improvements" across the primary and all key secondary endpoints. The firm, which thinks the SUMMIT data "hit the home run scenario," notes that its prior survey work suggests about a $1B opportunity for bezuclastinib "in ISM alone."

Leerink

Outperform

maintain

$16 -> $18

2025-07-07

Reason

Leerink

Price Target

$16 -> $18

2025-07-07

maintain

Outperform

Reason

Leerink raised the firm's price target on Cogent Biosciences to $18 from $16 and keeps an Outperform rating on the share after the company reported topline results from SUMMIT Part 2, the pivotal trial of bezuclastinib in indolent systemic mastocytosis. While the efficacy on a placebo-adjusted rate was in line with the firm's expectations, safety was better than anticipated, positioning the stock well for the APEX and PEAK readouts in the second half of 2025 and year-end 2025, respectively.

Citi

maintain

$15

2025-06-30

Reason

Citi

Price Target

$15

2025-06-30

maintain

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cogent Biosciences Inc (COGT.O) is -5.64, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess Cogent Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.00

Current PE

-5.64

Overvalued PE

-2.10

Undervalued PE

-7.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.31

Current EV/EBITDA

-7.07

Overvalued EV/EBITDA

0.48

Undervalued EV/EBITDA

-3.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

32738.02

Current PS

0.00

Overvalued PS

226312.13

Undervalued PS

-160836.09